Prospective Study
Copyright ©The Author(s) 2024.
World J Radiol. Dec 28, 2024; 16(12): 771-781
Published online Dec 28, 2024. doi: 10.4329/wjr.v16.i12.771
Table 1 Computed tomography severity scoring index
Items
Value
Disease limited to nose/PNS
    Mucosal disease in paranasal sinuses1
    Mucosal disease in nasal cavity and nasopharynx1
Adjacent tissue invasion
    Hard palate erosion1
    Soft tissue infiltration anterior/posterior periantral fat1
    Soft tissue infiltration extending to PPF/SOF/IOF/Orbital apex/ITF2
    Significant bilateral disease2
Orbit
    Soft tissue/fat/muscle/NLD involvement1
    Bone erosion2
    Intraocular/optic nerve involvement3
Intracranial disease
    Skull base invasion (erosion)2
    Cavernous sinus involvement3
    Internal carotid artery narrowing/occlusion3
    Intracranial complications (meningitis/cerebritis/abscess/infarct)3
Table 2 Demographic details

Parameter
Criteria
n (%)
1GenderMale:Female56 (84.85):10 (15.15)
2Periorbital swellingAbsent:Present29 (43.94):37 (56.06)
3Periorbital painAbsent:Present16 (24.24):50 (75.76)
4Facial numbnessAbsent:Present24 (36.36):42 (63.64)
5Extra-ocular movementsNormal:Restricted:Frozen29 (43.94):20 (30.3):17 (25.76)
6Vision statusNormal:Reduced:FCCF:PL Negative26 (39.39):21 (31.82):1 (1.52):18 (27.27)
7ProptosisAbsent:Present44 (66.67):22 (33.33)
8Palatal involvementAbsent:Present45 (68.18):21 (31.82)
9Cranial nerve InvolvementAbsent:Present48 (72.73):18 (27.27)
10PtosisAbsent:Present39 (59.09):27 (40.91)
11H/o diabetesAbsent:Present15 (22.73):51 (77.27)
12H/o hypertensionAbsent:Present43 (65.15):23 (34.85)
13HbA1c< 6.5:≥ 6.510 (15.15) 56 (84.85)
14Side involvedUnilateral:Bilateral60 (90.91):6 (9.09)
15CT severity indexMild (1-8):Moderate (9-16):Severe (≥ 17)34 (51.52):28 (42.42):4 (6.06)
16Final organismMucormycosis:Aspergillosis:Both45 (68.18):9 (13.64):12 (18.18)
17Clinical outcomeResponder:Non-responder43 (65.15):23 (34.85)
18SurvivalSurvived:Expired56 (84.85):10 (15.15)
19Diagnosis of COVID-19 before IFSAfter:Before9 (13.63):57 (86.36)
20EnvironmentRural:Urban20 (30.3):46 (69.7)
21TALMI stagingStage 1:Stage 2:Stage 3:Stage 42 (3.03):31 (46.97):7 (10.61):26 (39.39)
22Steroid given for COVID-19 (n = 57)Not given:Given24 (42.1):33 (57.89)
Table 3 Comparison of severity of disease in different etiological agents, n (%)
Parameter
Subclassification of parameter
Aspergillosis (n = 9)
Mucormycosis (n = 45)
Mixed (n = 12)
Diabetes mellitus3 (33.3)37 (82.2)11 (91.7)
Hypertension2 (22.2)16 (35.6)5 (41.7)
LateralityUnilateral9 (100)40 (89.9)11 (91.7)
Bilateral0 (0)5 (10.1)1 (8.3)
CTSIMild7 (77.8)21 (46.7)6 (50)
Moderate2 (22.2)21 (46.7)5 (41.7)
Severe0 (0)3 (6.7)1 (8.3)
SurvivalSurvival8 (88.9)38 (84.4)10 (83.3)
Mortality1 (11.1)7 (15.6)2 (16.7)
Responder/non-responderResponder7 (77.8)27 (60)9 (75)
Non-responder2 (22.2)18 (40)3 (25)
Table 4 Correlation with survival and death
Parameter
Criteria
Survivor
Expired
Total
P value (Fischer's exact test)
Diabetes mellitusAbsent14115
Present429510.28
HypertensionAbsent36743
Present203230.52
LateralityUnilateral54660
Bilateral2460.004
OrganismMucormycosis38745
Aspergillosis819
Mixed102121
Clinical responseResponder38543
Non-responder185230.23
TALMI stagingStage 1202
Stage 229231
Stage 3527
Stage 4206260.16
CTSIMild (1 to 8)29534
Moderate (9 to 16)25328
Severe (17 or more)2240.12
Table 5 Correlation with Responder and Non-responder.
Parameter
Criteria
Responder
Non-responder
Total
P value (Fischer's exact test)
Diabetes mellitusAbsent12315
Present3120510.14
HypertensionAbsent271643
Present167230.39
LateralityUnilateral421860
Bilateral1560.02
OrganismMucormycosis271845
Aspergillosis729
Mixed93120.53
SurvivalSurvivor381856
Expired55100.23
TALMI StagingStage 1202
Stage 222931
Stage 3437
Stage 41511260.58
CTSIMild (1 to 8)31334
Moderate (9 to 16)121628
Severe (17 or more)0440.00